Bronchoscopic Evaluation of a Steerable Needle for Simulated Tumor Targets in the Lung Periphery: A Feasibility Study (Bullseye).

Authors:
Chen AC; Machuzak M; Cheng G; Wahidi MM.

Journal:
Respiration

Publication Year: 2023

DOI:
10.1159/000529245

PMCID:
PMC10129018

PMID:
36996776

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Respiration

Abbreviation: Respiration

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Photon Counting Computed Tomography with the Radiation Dose of a Chest X-Ray: Feasibility and Diagn…
Dettmer S; Werncke T; Mitkovska VN and 6 more (2024) - Transparency Score: 3/6
Centrilobular Emphysema Is Associated with Pectoralis Muscle Reduction in Current Smokers without A…
Maetani T; Tanabe N; Shiraishi Y and 11 more (2023) - Transparency Score: 3/6
Evaluation of Bone Mineral Density in Lung Transplant Recipients by Chest Computed Tomography.
Mori R; Handa T; Ohsumi A and 16 more (2023) - Transparency Score: 3/6
Impact of Endobronchial Valve Treatment on Lung Function Decline.
Hartman JE; Klooster K; Koster TD and 3 more (2023) - Transparency Score: 3/6
Real-World Characteristics of Patients with Severe Asthma prior to Starting Dupilumab: The ProVENT …
Korn S; Schmidt O; Timmermann H and 8 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest Statement Alexander Chen, Michael Machuzak, George Cheng, and Momen Wahidi have received consulting fees from Serpex."

Evidence found in paper:

"Alexander Chen, Michael Machuzak, George Cheng, and Momen Wahidi have received consulting fees from the Sponsor of this study, Serpex. No additional funding was received."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025